Valiant Organics Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in newspapers on Sunday, May 17, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in the Financial Express (English edition) and Mumbai Lakshadeep (Marathi edition). The company returned to profitability in FY26, recording a standalone net profit of ₹3,435.56 lakh compared to a net loss of ₹299.84 lakh in the previous fiscal year, supported by revenue from operations that increased to ₹73,838.31 lakh from ₹71,876.18 lakh in FY25.

Financial Performance

Total income for the year ended March 31, 2026, grew to ₹74,529.79 lakh from ₹72,701.54 lakh in the prior year. Total expenses decreased to ₹70,795.98 lakh from ₹72,460.55 lakh, while profit before tax improved substantially to ₹4,305.89 lakh from ₹240.99 lakh. The financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on Saturday, May 16, 2026. The statutory auditors, M/s. Gokhale & Sathe, issued an audit report with an un-modified opinion for the financial year ended March 31, 2026.

Standalone Financial Results

The table below summarises the key standalone financial metrics for the year ended March 31, 2026:

For the quarter ended March 31, 2026, standalone net profit stood at ₹1,511.74 lakh, a significant rise from ₹395.62 lakh in the corresponding quarter of the previous year. Total income from operations for the quarter reached ₹22,170.99 lakh, up from ₹20,447.93 lakh in the same period last year.

Consolidated Financial Results

On a consolidated basis, total income from operations for the year ended March 31, 2026, stood at ₹74,567.86 lakh. Consolidated net profit after tax for the year was ₹3,322.85 lakh, compared to a net loss of ₹(299.84) lakh in the prior year on a standalone basis. Total comprehensive income on a consolidated basis for the year was ₹3,327.40 lakh. The consolidated net worth stood at ₹72,526.26 lakh, while reserves (excluding revaluation reserve) were ₹69,725.80 lakh.

Segment Reporting

Based on internal reports, the Board approved the identification of the Pharma Business as an additional reportable segment alongside the existing Specialty Chemicals segment, in accordance with Ind AS 108. For the year ended March 31, 2026, the Specialty Chemical Division reported revenue of ₹57,481.94 lakh, while the newly identified Pharma Division reported revenue of ₹16,356.38 lakh. The company also received ₹852.76 lakhs towards a fire insurance claim settlement during the year, with ₹572.08 lakhs recognised under exceptional items. The full format of the audited financial results is available on the company's website at www.valiantorganics.com and on the BSE and NSE websites.

Valiant Organics Limited has announced that its Board of Directors, at a meeting held on May 16, 2026, accorded its in-principle approval to explore potential restructuring options amongst the company, its subsidiaries, and associates. The board meeting commenced at 12.50 P.M. (IST) and concluded at 2.45 P.M. (IST). The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scope of Restructuring Evaluation

The restructuring evaluation encompasses a broad range of corporate arrangements that may be implemented in one or more tranches, transactions, or combinations. The company has stated that the process is subject to applicable law and requisite approvals, and does not constitute a commitment to implement any restructuring. The following table summarizes the key parameters of the announced evaluation:

Strategic Objectives Identified by the Board

The Board has identified a set of broad strategic objectives to guide the evaluation process. These principles reflect the company's intent to optimize its corporate and operational structure while creating long-term stakeholder value. The key objectives include:

• Unlocking long-term value for shareholders and other stakeholders through simplification of the existing structure
• Creating strategically aligned business platforms better positioned to capitalize on distinct market opportunities
• Enhancing clarity of business and investment profiles to facilitate improved stakeholder understanding and wider investor participation
• Sharpening strategic focus on core competencies through suitable realignment and optimization of business and resources, with a view to enhancing efficiency and realizing structural and operational synergies
• Exploring tax-efficient and compliant structures that support the above objectives and mitigate complexity in future corporate actions

As part of this evaluation, the company is also potentially considering certain changes to existing economic interests and inter-se holding arrangements, subject to finalization of terms and conditions and receipt of required approvals.

Next Steps and Disclosure Commitments

Valiant Organics has stated that the matter will be further evaluated, following which the Board of Directors will be apprised of the outcomes to determine the future course of action, if any. The company has committed to making appropriate announcements and public disclosures as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, from time to time.

About Valiant Organics Limited

Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered in Mumbai, India, with 6 (six) manufacturing units across the country. The company is focused on the manufacturing and marketing of specialty chemicals used across end-industries including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications. Key chemistries employed include chlorination, hydrogenation, ammonolysis, acetylation, sulphonation, and methoxylation, among others. The company has primarily focused on manufacturing specialty chemicals that have significant demand-supply gaps and where domestic manufacturing can serve as an alternative to imports.